Lipella pharmaceuticals announces completion of first cohort in phase 2a trial of lp-310 for oral lichen planus, advancing to next dose group

Pittsburgh, nov. 21, 2024 (globe newswire) -- lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company focused on innovative therapies for serious diseases with significant unmet needs, today announced the completion of dosing for the first cohort in its multi-center phase 2a clinical trial of lp-310, a liposomal-tacrolimus oral rinse being developed for the treatment of oral lichen planus (olp). in this first cohort, eight participants received a dose of 0.25 mg lp-310, with promising initial results.
LIPO Ratings Summary
LIPO Quant Ranking